Abiomed's heart pump gets EU nod
(Reuters) - Abiomed Inc said European health regulators approved the use of its heart pump in cardiac surgery.
The Danvers, Massachusetts-based company said the device, called Impella cVAD, is expected to be commercially available in Europe by this summer.
The device is intended for use in cardiac surgery for supporting the weakened heart's left ventricle, which is responsible for pumping oxygen-rich blood from the lungs throughout the body.
Impella cVAD is still not approved in the United States.
Abiomed shares closed at $20.90 on Wednesday on the Nasdaq.
(Reporting by Anand Basu in Bangalore; Editing by Viraj Nair)
- Tweet this
- Share this
- Digg this
- Malaysia military tracked missing plane to west coast - source
- Rupee falls after sources say plan to join global debt index on hold
- UPDATE 5-GM hires law firms it works with to probe recall response
- Malaysia air probe finds scant evidence of attack - sources
- India halts plan to join global bond indexes, defers Euroclear - sources
Made by local firm Lomus Pharmaceuticals and backed by the government, the U.S. aid agency and other donors, "Navi Malam" gel was introduced in 2011 in hospitals across Nepal and has helped to reduce the number of babies dying from umbilical cord infection. Trials have shown a 23 percent drop in newborn deaths due to infection since the gel was introduced, according to USAID. Full Article